Open AccessObjective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
Author(s) -
Ciara M. Kelly,
Cristina R. Antonescu,
Timothy G. Bowler,
Rodrigo Ramella Munhoz,
Ping Chi,
Mark A. Dickson,
Mrinal M. Gounder,
Mary Louise Keohan,
Sujana Movva,
Reena Dholakia,
Hamza Ahmad,
Matthew D. Biniakewitz,
Mercedes M. Condy,
Haley T. Phelan,
Margaret K. Callahan,
Phillip Wong,
S. J. Singer,
Charlotte E. Ariyan,
Edmund K. Bartlett,
Aimeé M. Crago,
Sam S. Yoon,
Sinchun Hwang,
Joseph P. Erinjeri,
LiXuan Qin,
William D. Tap,
Sandra P. D’Angelo
Publication year - 2020
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2019.6152
Subject(s) - medicine , pembrolizumab , oncology , sarcoma , immunotherapy , cancer , pathology
Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom